{"id":"beva-soc","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Hypertension"},{"rate":"15-25","effect":"Proteinuria"},{"rate":"5-10","effect":"Bleeding/hemorrhage"},{"rate":"5-8","effect":"Thrombotic events"},{"rate":"30-50","effect":"Chemotherapy-related neutropenia"},{"rate":"20-30","effect":"Fatigue"},{"rate":"15-25","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bevacizumab blocks vascular endothelial growth factor (VEGF), preventing new blood vessel formation that tumors depend on for growth and metastasis. When combined with standard chemotherapy regimens, this dual approach targets both tumor vasculature and cancer cells directly, potentially improving overall survival and progression-free survival in solid tumors.","oneSentence":"BEVA+SOC combines bevacizumab (an anti-VEGF monoclonal antibody) with standard of care chemotherapy to inhibit tumor angiogenesis and improve chemotherapy efficacy.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:04:03.566Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer (bevacizumab + standard chemotherapy)"},{"name":"Metastatic non-small cell lung cancer (bevacizumab + standard chemotherapy)"}]},"trialDetails":[{"nctId":"NCT04822818","phase":"PHASE3","title":"EFFICACY and SAFETY OF BEVACIZUMAB (ZIRABEV®) IN PATIENTS WITH SEVERE HYPOXEMIC COVID-19","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-04-17","conditions":"Corona Virus Infection, SARS (Severe Acute Respiratory Syndrome), Virus Diseases","enrollment":96}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"BEVA+SOC","genericName":"BEVA+SOC","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BEVA+SOC combines bevacizumab (an anti-VEGF monoclonal antibody) with standard of care chemotherapy to inhibit tumor angiogenesis and improve chemotherapy efficacy. Used for Metastatic colorectal cancer (bevacizumab + standard chemotherapy), Metastatic non-small cell lung cancer (bevacizumab + standard chemotherapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}